厄贝沙坦与开博通治疗糖尿病肾病的临床观察

目的探讨厄贝沙坦开博通治疗糖尿病肾病的疗效。方法选择60例2型糖尿病并发肾脏病变患者,随机分为厄贝沙坦治疗组(30例),与开搏通对照组(30例)。两组患者治疗前后监测血压、24h尿蛋白定量、血肌酐、尿素氮、血钾、血糖、血β2-MG、尿β2-MG等,疗程16周。结果两组病人治疗前后血压、24h尿蛋白定量、血β2-MG、尿β2-MG、血肌酐均有明显下降(P<0·05)。结论厄贝沙坦和开博通均有降压及肾脏保护作用,厄贝沙坦的肾脏保护作用优于开博通,而厄贝沙坦同时具有改善胰岛β细胞功能的作用。且厄贝沙坦副作用较小。

Clinical Observation on Treatment of Diabetic Nephropathy with Irbesartan and Captopril

Objective To discuss the curative effect of diabetic nephropathy treated with irbesartan and captopril. Methods 60 cases of nephropathy combined with diabetes II were divided into two groups (irbesartan group and captopril group) randomly 16 weeks as a course. The blood pressure, urine protein of 24 h, creatinie, BUN, potassium, glucose and so on were monitored. Results All the clinical data monitored had decreased in both groups (P<0.05). Conclusion The both drugs might have decreasing pressure and preventing kidney action. Irbesartan had strong protection on kidney than catopril and improving pancreas island function with less side effect.